Literature DB >> 27251566

Sustained Inflation and Its Role in the Delivery Room Management of Preterm Infants.

Gianluca Lista1, Paola Azzurra La Verde, Francesca Castoldi.   

Abstract

A noninvasive approach in the delivery room in place of intubation and mechanical ventilation can reduce rates of bronchopulmonary dysplasia and death. Nevertheless, the rate of nasal continuous positive airway pressure failure still remains high. In order to prevent lung injury and to enhance the success of continuous positive airway pressure, sustained inflation (administration by face mask or nasopharyngeal tube of a high peak pressure of 20-25 cm H2O, maintained for 10-15 s) has been recently proposed to establish an early and efficient functional residual capacity in the delivery room. Sustained inflation is an intriguing therapy, although the results of clinical trials are controversial in terms of respiratory outcomes. A critical role in the success of sustained inflation could be the presence of open or closed glottis and the contribution of spontaneous breathing that allows air to enter the lungs during the maneuver. Recent neonatal resuscitation guidelines suggest that sustained inflation may be considered in individual clinical circumstances or research settings.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 27251566     DOI: 10.1159/000444899

Source DB:  PubMed          Journal:  Neonatology        ISSN: 1661-7800            Impact factor:   4.035


  2 in total

Review 1.  Current insights in non-invasive ventilation for the treatment of neonatal respiratory disease.

Authors:  Dhivya Lakshmi Permall; Asfia Banu Pasha; Xiao-Qing Chen
Journal:  Ital J Pediatr       Date:  2019-08-19       Impact factor: 2.638

2.  Lung recruitment improves the efficacy of intubation-surfactant-extubation treatment for respiratory distress syndrome in preterm neonates, a randomized controlled trial.

Authors:  Yong Yang; Wenkang Yan; Minyi Ruan; Lan Zhang; Jinzhen Su; Haohui Deng; Minxu Li
Journal:  BMC Pediatr       Date:  2022-01-03       Impact factor: 2.125

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.